98 related articles for article (PubMed ID: 8751825)
1. Study of the role of iron in the anticryptococcal activity of human serum and fluconazole.
Grover DD; Brummer E; Stevens DA
Mycopathologia; 1996; 133(2):71-7. PubMed ID: 8751825
[TBL] [Abstract][Full Text] [Related]
2. Characterization of an anticryptococcal protein isolated from human serum.
Sridhar S; Ahluwalia M; Brummer E; Stevens DA
Infect Immun; 2000 Jun; 68(6):3787-91. PubMed ID: 10816550
[TBL] [Abstract][Full Text] [Related]
3. Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity.
Nassar F; Brummer E; Stevens DA
Antimicrob Agents Chemother; 1995 Nov; 39(11):2490-3. PubMed ID: 8585731
[TBL] [Abstract][Full Text] [Related]
4. Effect of iron on fluconazole activity against Candida albicans in presence of human serum or monocyte-derived macrophages.
Minn Y; Brummer E; Stevens DA
Mycopathologia; 1997; 138(1):29-35. PubMed ID: 9404022
[TBL] [Abstract][Full Text] [Related]
5. Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum.
Brummer E; Kamei K; Miyaji M
Mycopathologia; 1998; 142(1):3-7. PubMed ID: 9850592
[TBL] [Abstract][Full Text] [Related]
6. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
Vu K; Gelli A
Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterisation of an anticryptococcal protein in human cerebrospinal fluid.
Ahluwalia M; Brummer E; Sridhar S; Singh R; Stevens DA
J Med Microbiol; 2001 Jan; 50(1):83-89. PubMed ID: 11192510
[TBL] [Abstract][Full Text] [Related]
8. Gomesin, a peptide produced by the spider Acanthoscurria gomesiana, is a potent anticryptococcal agent that acts in synergism with fluconazole.
Barbosa FM; Daffre S; Maldonado RA; Miranda A; Nimrichter L; Rodrigues ML
FEMS Microbiol Lett; 2007 Sep; 274(2):279-86. PubMed ID: 17645524
[TBL] [Abstract][Full Text] [Related]
9. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
Klepser ME; Wolfe EJ; Pfaller MA
J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-macrophage colony-stimulating factor and fluconazole enhance anti-cryptococcal activity of monocytes from AIDS patients.
Tascini C; Vecchiarelli A; Preziosi R; Francisci D; Bistoni F; Baldelli F
AIDS; 1999 Jan; 13(1):49-55. PubMed ID: 10207544
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.
Butts A; Koselny K; Chabrier-Roselló Y; Semighini CP; Brown JC; Wang X; Annadurai S; DiDone L; Tabroff J; Childers WE; Abou-Gharbia M; Wellington M; Cardenas ME; Madhani HD; Heitman J; Krysan DJ
mBio; 2014 Feb; 5(1):e00765-13. PubMed ID: 24520056
[TBL] [Abstract][Full Text] [Related]
12. Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: synergy with fluconazole for killing.
Brummer E; Stevens DA
J Infect Dis; 1994 Jul; 170(1):173-9. PubMed ID: 8014494
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyaldimines as potent in vitro anticryptococcal agents.
Magalhães TF; da Silva CM; de Fátima Â; da Silva DL; Modolo LV; Martins CV; Alves RB; Ruiz AL; Longato GB; de Carvalho JE; de Resende-Stoianoff MA
Lett Appl Microbiol; 2013 Aug; 57(2):137-43. PubMed ID: 23594040
[TBL] [Abstract][Full Text] [Related]
14. Antifungal activity of cerebrospinal fluid against Cryptococcus neoformans and Candida species.
Brummer E; Drasin T; Adler JD; Stevens DA
Med Mycol; 1999 Oct; 37(5):339-44. PubMed ID: 10520158
[TBL] [Abstract][Full Text] [Related]
15. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation.
Levitz SM; Harrison TS; Tabuni A; Liu X
J Clin Invest; 1997 Sep; 100(6):1640-6. PubMed ID: 9294133
[TBL] [Abstract][Full Text] [Related]
16. Synergy of fluconazole with human monocytes or monocyte-derived macrophages for killing of Candida species.
Garcha UK; Brummer E; Stevens DA
J Infect Dis; 1995 Dec; 172(6):1620-3. PubMed ID: 7594731
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fluconazole minimum inhibitory concentrations in three different formulations of RPMI-1640.
Espinel-Ingroff A; Steele-Moore L
Diagn Microbiol Infect Dis; 1994 Oct; 20(2):87-91. PubMed ID: 7867310
[TBL] [Abstract][Full Text] [Related]
18. Effect of macrophage colony-stimulating factor on anticryptococcal activity of bronchoalveolar macrophages: synergy with fluconazole for killing.
Brummer E; Nassar F; Stevens DA
Antimicrob Agents Chemother; 1994 Sep; 38(9):2158-61. PubMed ID: 7811035
[TBL] [Abstract][Full Text] [Related]
19. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
Nielsen K; Vedula P; Smith KD; Meya DB; Garvey EP; Hoekstra WJ; Schotzinger RJ; Boulware DR
Med Mycol; 2017 Jun; 55(4):453-456. PubMed ID: 27664991
[TBL] [Abstract][Full Text] [Related]
20. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):87-93. PubMed ID: 11035239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
